Join to view full profile
230 S. Main StSuite 100Orange, CA 92868
Phone+1 714-541-0101
Fax+1 714-541-0450
Dr. Link is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 1972 - 1974
Keck School of Medicine of the University of Southern CaliforniaClass of 1972
Certifications & Licensure
CA State Medical License 1973 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification CGM CLINICAL™, CompuGroup Medical, 2015-2016
- CMS Meaningful Use Stage 1 Certification Alteer Office, CompuGroup Medical, 2015-2016
- Top MD Consumers Checkbook
Clinical Trials
- Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Dec 10
- NBRST: Prospective Neo-adjuvant REGISTRY Trial
- Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2013 Mar 07
Publications & Presentations
PubMed
- 162 citationsFinal Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.Arlene Chan, Beverly Moy, Janine Mansi, Bent Ejlertsen, Frankie A. Holmes
Clinical Breast Cancer. 2021-02-01 - 426 citationsNeratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3...Miguel Martin, Frankie A. Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy
The Lancet. Oncology. 2017-12-01 - 44 citationsA phase 1, randomized, dose‐ranging study of GS‐5816, a once‐daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virusEric Lawitz, B. Freilich, John O. Link, P. German, Hongmei Mo
Journal of Viral Hepatitis. 2015-12-01
Press Mentions
Dr. John Link to Speak at Cancer Support Community PasadenaJanuary 8th, 2018
These SCNG Columnists Are Cancer Stars. Here’s How to Hear Their StoriesJune 4th, 2023- 2 SCNG Columnists Among Those Honored at Long Beach Cancer League GalaJune 5th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
